Is eHealth, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for eHealth, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 6, a price-to-book value of 0.20, and an EV to EBITDA ratio of 0.40, all of which suggest that the stock is trading at a significant discount relative to its earnings and assets.
In comparison to its peer, Abacus Life, Inc., which has a much higher P/E ratio of 164.30 and an EV to EBITDA of 18.86, eHealth, Inc. stands out as a more compelling investment opportunity. Additionally, the PEG ratio of 0.02 further emphasizes its undervaluation relative to growth expectations. However, it is worth noting that eHealth's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -47.55% compared to the index's 16.30%, although it has shown a positive return of 1.44% over the past year.